Compare Bristol-Myers Squibb Co (BMY) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Materials Select Sector SPDR Fund — how do they compare? Bristol-Myers Squibb Co trades at $63.95 (market cap $129.94B), while Materials Select Sector SPDR Fund trades at $53.17. The key difference: Bristol-Myers Squibb Co pays a 3.96% dividend while Materials Select Sector SPDR Fund pays none. Which is the better fit depends on your goals.
| BMY | XLB | |
|---|---|---|
Market Cap | $129.94B | — |
Sector | Health | — |
52-Week High | $65.89 | $53.62 |
52-Week Low | $42.60 | $42.23 |
Enterprise Value | $163.92B | — |
Dividend Yield | 3.96% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $63.88, down 1.48% on the day, with strong technical momentum indicated by bullish moving averages and ADX signals. The company demonstrates robust fundamentals with a 14.01 P/E ratio, 18.87% net income margin, and consistent earnings beats in recent quarters. Recent developments include a $2.3 billion manufacturing investment in Houston and strategic AI collaboration with Schrödinger.
BMY presents a compelling investment case with attractive valuation metrics and strong profitability, though investors face risks from patent expirations and debt levels. Analyst consensus suggests 7% upside to the $68.56 price target, with the stock offering dividend income alongside growth potential from pipeline developments and potential M&A activity.
XLB trades at $52.58, down 1.13% on the day, with a bullish technical signal from moving averages but mixed oscillator readings. The stock recently crossed below its 200-day moving average, signaling potential trend change. A dividend of $0.19 is scheduled for June 2026. Recent news highlights materials sector strength from AI infrastructure demand and geopolitical supply chain shifts.
Outlook remains cautiously optimistic given sector tailwinds from AI and infrastructure spending, though cyclical risks and valuation concerns after recent gains pose headwinds. The technical setup suggests near-term consolidation around $53 support with resistance at $54.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
